Introduction: Collagenase clostridium histolyticum (CCH) is the first and only licensed medical treatment for men with Peyronie's disease (PD). Published literature shows intralesional CCH injection as an effective and safe minimally invasive treatment in a specific subgroup of PD patients.Areas covered: The authors discuss pharmacodynamics and pharmacokinetics as well as clinical outcomes and safety profile from major CCH studies in PD. All relevant CCH studies published in PubMed and EMBASE databases up to June 2019 were included.Expert opinion: Given the variability in treatment schedule and drug access coupled with the potential need for further treatment, strict patient selection and the use of adjunctive strategies are key determinants to maximize clinical efficacy of intralesional CCH. Furthermore, longer-term follow-up data on the clinical outcomes, safety and durability of CCH in larger multi-center studies and post-marketing surveillance data are necessary to provide a comparison to other standard PD treatment options.

中文翻译：

---

有关胶原酶溶组织梭状芽孢杆菌和Peyronie病的最新研究：药物概况，临床证据和安全性结果。

简介：胶原酶溶组织性梭状芽胞杆菌（CCH）是第一种也是唯一一种被许可用于男性佩罗尼氏病（PD）的药物治疗。已发表的文献显示病灶内CCH注射是PD患者特定亚组中一种有效且安全的微创治疗方法。研究范围：作者讨论了PD的主要CCH研究的药效学和药代动力学以及临床结果和安全性。截止到2019年6月，PubMed和EMBASE数据库中发表的所有相关CCH研究均包括在内。专家意见：鉴于治疗方案和药物获取的可变性以及潜在的进一步治疗需求，严格的患者选择和辅助策略的使用是关键决定因素使病变内CCH的临床疗效最大化。此外，